Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 16 · below the Ichimoku cloud · RSI 38 · MACD below its signal
None of the 29 investors followed here reported a position in GELS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GELS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for GELS.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 21.3 | -22.0 | -12.7 | -2.4 | -24.2 | 37.0 | -22.4 | 5.0 | -2.9 | -11.3 | −41.3% | ||
| 2025 | -3.0 | -27.1 | -36.6 | 102.9 | -24.2 | 8.1 | 0.0 | -27.6 | 10.2 | -14.5 | -8.5 | -25.9 | −65.5% |
| 2024 | -21.9 | 16.0 | −9.4% |
No analyst coverage for this instrument.
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.